RegMed Investors’ (RMi) closing bell analysis, the sector flipped positive in the session’s last hour!

November 21, 2016 5:30pm

… While testing volume, moving averages, fundamentals, resistance and expectation

And with tight trading ranges

I answer one question; in which company should investors put, keep and commit their money!

Pre-open indication’s tally:  2 hits (AGTC and IMUC) and 3 miss (AST, CAPR and BLCM)

Lose an advantage or be a subscriber!  Today’s results have implications to Tuesday's sector activity.   

I say today what others won't, so you can do what others can't whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.

There are two things that investors need - interpretation of news and translation of market metrics concerning the stem, cell, gene and regenerative therapy sector to substantiate share pricing.

U.S. equities closed higher on Monday, led by energy stocks, as oil prices rose on renewed optimism that OPEC was closing in on a deal to cut production

The NASDAQ closed UP +47.35 or +0.89% to 5,369.86 and the DOW closed UP +89.03 or +0.47% to 18,956.96.

A day in the life of the stem, cell, gene and regenerative therapy (SCGT & RT) sector – the advance/decline line scenario of our 43 covered companies:   

• The open was negative with an A/DL of 17/20 and 6 flats;                     
• The mid-day stayed negative with an A/DL of 16/25 and 2 flats;
• The closing bell was positive with A/DL of 27/15 and 2 flats;

Henry’omics:

The stem, cell, gene and regenerative therapy (SCG&RT) sector opened negative, stayed negative at the mid-day and closed positive.

• From this morning’s investor’s letter, “Newest highs question the tenor of uncertainty … It’s complicated, after all the losses; don’t assume the worst, as the market is even less sure of whether “our” universe is going forward.”

The last time all three indexes (DOW, S&P and NASDAQ) closed at record highs at the same time was two sessions back in mid-August, and before then had not occurred since 1999.

• The Russell 2000 index (RUT) finished at a record of 1,322.20, a gain of 6.56 points, or 0.5%. The index of small stocks outperformed its large-cap counterpart year to date, rising more than 16% since January, compared with 7.6% for the S&P 500.

The CBOE Volatility Index (VIX), widely considered the best gauge of fear in the market, traded flat, near 12.5.

• The iShares Russell 2000 (IWM) indicated a positive pre- open of +0.10% and closed UP +0.47% while the iShares NASDAQ Biotechnology (IBB) indicate a pre-open negative of -0.15% and closed UP +0.70%.

A pause for reflection could come as Tuesday closes and when volume traditionally thins out as traders head out for the Thanksgiving Day holiday.  

• Markets will shut Thursday and then close early on Black Friday, the traditional kickoff to holiday shopping.

At the close …

• Gainers included ImmunoCellular (NYSEMKT: IMUC +$3.23), Kite Pharma (KITE +$1.88), Juno Therapeutics (JUNO +$1.51), Stemline (STML +$1.50) and Opexa (OPXA +$0.80), contributed the most gains;

• The biggest losers of the session were Adverum (ADVM -0.55), AxoGen (AXGN -$0.35), Cesca Therapeutics (KOOL -0.22), Mesoblast (MESO -$0.18) and Intrexon (XON -$0.18)

The downside trend reflects a pricing trend range of:

• Monday’s decliners ranged from -0.58% <XON> to -15.49% <ADVM> in 15 equities;
• Friday’s decliners ranged from -0.31% <ONVO>to -12.34% <NWBO>in 17 equities
• Thursday’s decliners ranged from -0.78% <JUNO> to-21.28% <STEM> in 15 equities;
• Wednesday’s decliners ranged from -0.42% <STML> to -14.93% <IMUC> in 26 equities;
• Tuesday’s decliners ranged from -0.02% <OPXA> to -9.52% <RENE.L> in 27 equities;
• Last Monday’s decliners ranged from –o.21% <CLLS> to -6.48% <FATE> in 17 equities;

The upside shows a pricing trend range of:

• Monday’s gainers ranged from +0.14% <QURE> to +4831.3% (IMUC – after a reverse split> in 26 equities;
• Friday’s gainers ranged from +0.21% <MESO> to +21.82% <OPXA> in 24 equities;
• Thursday’s gainers ranged from +0.14% <IMUC> to +12.50% in 28 equities;
• Wednesday’s gainers ranged from +0.46% <OSIR> to +31.78% <STEM> to in 13 equities;
• Tuesday’s gainers ranged from +0.58% <AXGN> to +11.11% <CLBS> in 13 equities
• Last Monday’s gainers ranged from +0.59% <ATHX> to +15.62% <CAPR> <> in 23 equities;

Wrap-up: anybody can read a paragraph … review the percentage changes per day in the week of the decliners and advancers.

• Monday’s 26 gainers compared to Friday’s 24 following Thursday’s 28 following Wednesday’s 13 post Tuesday’s 13 followed last Monday’s 23 …

• Monday’s 15 decliners followed Friday’s 17 as compared to Thursday’s 15 following Wednesday’s 26 after Tuesday’s 27 decliners post Monday’s 17...

Pre-open indication’s tally:  2 hits (AGTC and IMUC) and 3 miss (AST, CAPR and BLCM)

• Applied Genetic Technologies (AGTC) closed DOWN -$0.075 – hit;
• Asterias Biotherapeutics (NYSEMKT: AST) closed UP +$0.09 – miss;
• Bellicum Pharmaceuticals (BLCM) closed UP +$0.28 – miss;
• Capricor (CAPR) closed UP +$0.02 – miss;
• ImmunoCellular (NYSEMKT: IMUC) closed UP +$3.164 – hit;

Percentage decliners:

• Adverum (ADVM) -15.49%;
• Cesca Therapeutics (KOOL) -6.85% after Friday’s -5.31% after Thursday’s +7.62%;
• Vericel (VCEL) -4.17%;
• Neuralstem (CUR) -4.11%;
• AxoGen (AXGN) -3.93%

Percentage advancers:

• ImmunoCellular (NYSEMKT: IMUC) +4938.17% after Friday’s -6.56% - reason, a reverse split – 40 into 1 in common stock;
• Opexa (OPXA) +119.4% after Friday’s +21.82% after Thursday’s -6.76% after Wednesday’s +5.34%;
• Stemline (STML) +12.30%;
• Northwest Bio (NWBO) +8.06% after Friday’s -12.34%;
• Fibrocell (FCSC) +7.15% after Friday’s +13.42%;

Flat:                                                                                                      

• Athersys (ATHX) at $1.81

Review my fear gauge or the CBOE Volatility Index (VIX):

·         Monday traded 12.5;

·         Friday traded near 13.2;

·         Thursday traded near 13.5;

·         Wednesday traded near 13.9;

·         Tuesday traded near 13.4;

·         Last Monday traded near 14.9;

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.